ArticleOphthalmology2023

Re: Freedman et al: Low- and very low-dose bevacizumab for retinopathy of prematurity: reactivations, additional treatments, and 12-month outcomes (Ophthalmology. 2022;129:1120-1128).

Víctor Manuel Asensio-SánchezPubMed ↗Publisher ↗

No numbers read from the abstract.